Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | dopamine receptor D2 | Starlite/ChEMBL | References |
Rattus norvegicus | Serotonin transporter | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | Matrilysin homolog | 0.5939 | 0.4967 | 1 |
Onchocerca volvulus | 0.3797 | 0.2127 | 0.3431 | |
Brugia malayi | Matrixin family protein | 0.6474 | 0.5676 | 1 |
Mycobacterium leprae | PROBABLE HYDROLASE | 0.3261 | 0.1417 | 0.5 |
Brugia malayi | Matrix metalloprotease, N-terminal domain containing protein | 0.3261 | 0.1417 | 0.1537 |
Schistosoma mansoni | hypothetical protein | 0.3797 | 0.2127 | 1 |
Mycobacterium ulcerans | hydrolase | 0.3261 | 0.1417 | 0.5 |
Brugia malayi | Hemopexin family protein | 0.3797 | 0.2127 | 0.2947 |
Echinococcus multilocularis | matrix metallopeptidase 7 (M10 family) | 0.9735 | 1 | 0.5 |
Schistosoma mansoni | matrix metallopeptidase-7 (M10 family) | 0.2678 | 0.0643 | 0.3024 |
Loa Loa (eye worm) | matrixin family protein | 0.5939 | 0.4967 | 0.859 |
Mycobacterium tuberculosis | Probable peptidoglycan hydrolase | 0.3261 | 0.1417 | 0.5 |
Loa Loa (eye worm) | matrixin family protein | 0.6474 | 0.5676 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.3261 | 0.1417 | 0.1537 |
Onchocerca volvulus | Matrix metalloproteinase homolog | 0.5939 | 0.4967 | 1 |
Wolbachia endosymbiont of Brugia malayi | extracellular metallopeptidase | 0.918 | 0.9264 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 0.9 mg kg-1 | Effective dose against apomorphine-induced climbing behavior in mice upon oral administration (Dopaminergic antagonist) | ChEMBL. | 16250644 |
ED50 (functional) | = 0.9 mg kg-1 | Effective dose against apomorphine-induced climbing behavior in mice upon oral administration (Dopaminergic antagonist) | ChEMBL. | 16250644 |
ED50 (functional) | = 30 mg kg-1 | Effective dose against potentiation of 5-HTP induced serotonin syndrome in mice upon oral administration (Serotonin reuptake inhibitory activity) | ChEMBL. | 16250644 |
ED50 (functional) | = 30 mg kg-1 | Effective dose against potentiation of 5-HTP induced serotonin syndrome in mice upon oral administration (Serotonin reuptake inhibitory activity) | ChEMBL. | 16250644 |
Ki (binding) | = 0.6 nM | In vitro inhibitory constant against [3H]-paroxetine binding to rat frontal cortex membrane serotonin reuptake site | ChEMBL. | 16250644 |
Ki (binding) | = 0.6 nM | In vitro inhibitory constant against [3H]-paroxetine binding to rat frontal cortex membrane serotonin reuptake site | ChEMBL. | 16250644 |
Ki (binding) | = 4.3 nM | In vitro inhibitory constant against [3H]-spiperone binding to human dopamine D2 receptor expressed in CHO cells | ChEMBL. | 16250644 |
Ki (binding) | = 4.3 nM | In vitro inhibitory constant against [3H]-spiperone binding to human dopamine D2 receptor expressed in CHO cells | ChEMBL. | 16250644 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.